RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.

doi:10.1038/ncomms7377

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.

Nature communications - 11 Mar 2015

Niederst Matthew J, Sequist Lecia V, Poirier John T, Mermel Craig H, Lockerman Elizabeth L, Garcia Angel R, Katayama Ryohei, Costa Carlotta, Ross Kenneth N, Moran Teresa, Howe Emily, Fulton Linnea E, Mulvey Hillary E, Bernardo Lindsay A, Mohamoud Farhiya, Miyoshi Norikatsu, VanderLaan Paul A, Costa Daniel B, Jänne Pasi A, Borger Darrell R, Ramaswamy Sridhar, Shioda Toshi, Iafrate Anthony J, Getz Gad, Rudin Charles M, Mino-Kenudson Mari, Engelman Jeffrey A

Abstract excerpt

Tyrosine kinase inhibitors are effective treatments for non-small-cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutations. However, relapse typically occurs after an average of 1 year of continuous treatment. A fundamental histological transformation from NSCLC to small-cell lung cancer (SCLC) is observed in a subset of the resistant cancers, but the molecular changes associated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aniline Compounds

Share to bcl-X Protein

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Proto-Oncogene Proteins c-bcl-2

Share to Retinoblastoma Protein

Share to Small Cell Lung Carcinoma

Source

Open in PubMed Open full text

Identifiers

PMID: 25758528
DOI: 10.1038/ncomms7377
PMCID: PMC4357281

Genes

EGFR
BCL2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.PMID 25758528Read ↗

Molecular mechanisms and therapeutic strategies for small‑cell lung cancer transformation after TKI therapy in EGFR‑mutated lung adenocarcinoma (Review)Semantic proximity Read ↗

[Research Advances on Transformation to Small Cell Lung Cancer].Semantic proximity Read ↗

Rare transformation from lung adenocarcinoma to sarcomatoid carcinoma mediates resistance to inhibitors targeting different driver oncogenesSemantic proximity Read ↗

Current knowledge of small cell lung cancer transformation from non-small cell lung cancer.Semantic proximity Read ↗

Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markersSemantic proximity Read ↗

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.Semantic proximity Read ↗

Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in EGFR-Mutant Non-small Cell Lung CancerSemantic proximity Read ↗

Histologic Transformation in EGFR-Mutant Lung Adenocarcinomas: Mechanisms and Therapeutic ImplicationsSemantic proximity Read ↗

Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung CancerSemantic proximity Read ↗

P53 and Rb Aberrations in Small Cell Lung Cancer (SCLC): From Molecular Mechanisms to Therapeutic ModulationSemantic proximity Read ↗

Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case reportSemantic proximity Read ↗

Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.